Fulvestrant for advanced breast cancer: A meta-analysis

Cancer Treatment Reviews

Volumn 39, Issue 7, 2013, Pages 753-758

  Al Mubarak, Mustafa ^a,b   Sacher, Adrian G ^a   Ocana, Alberto ^c   Vera Badillo, Francisco ^a   Seruga, Bostjan ^d   Amir, Eitan ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b Ministry of Education Saudi Arabia   (Saudi Arabia)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^d INSTITUTE OF ONCOLOGY   (Slovenia)

Author keywords

Aromatase inhibitors; Breast cancer; Fulvestrant; Tamoxifen

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; FULVESTRANT; TAMOXIFEN;

ARTHRALGIA; ASTHENIA; BREAST CANCER; CANCER HORMONE THERAPY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; META ANALYSIS; MONOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT OUTCOME; VEIN THROMBOSIS;

AROMATASE INHIBITORS; BREAST CANCER; FULVESTRANT; TAMOXIFEN;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; DISEASE PROGRESSION; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; NEOPLASM STAGING; TREATMENT OUTCOME;

EID: 84881551484     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.03.004     Document Type: Review

References (30)

1. Wakeling A.E. Similarities and distinctions in the mode of action of different classes of antioestrogens. Endocr Relat Cancer 2000, 7(1):17-28.
2. Osborne C.K., et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995, 87(10):746-750.
3. Howell A., et al. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet 1995, 345(8941):29-30.
4. Howell A., et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002, 20(16):3396-3403.
5. Osborne C.K., et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002, 20(16):3386-3395.
6. Howell A., et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol 2004, 22(9):1605-1613.
7. Robertson J.F. Fulvestrant (Faslodex) - how to make a good drug better. Oncologist 2007, 12(7):774-784.
8. Chia S., et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008, 26(10):1664-1670.
9. Johnston S et al. Fulvestrant alone or with concomitant anastrozole vs exemestane following progression on non-steroidal aromatase inhibitor - first results of the SoFEa trial (CRUKE/03/021 & CRUK/09/007) (ISRCTN44195747). Abstract LBA2, presented at EBCC-8, 2012.
10. Bergh J., et al. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012, 30(16):1919-1925.
11. Mehta R.S., et al. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012, 367(5):435-444.
12. Di Leo A., et al. Results of the CONFIRM phase III trial comparing fulvestrant 250mg with fulvestrant 500mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010, 28(30):4594-4600.
13. Di Leo A, Jerusalem G, Petruzelka L, et al. Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500mg versus 250mg. San Antonio Breast Cancer Symposium, San Antonio (TX), December 4-8; 2012 (Abstract S1-4).
14. FASLODEX® (fulvestrant) injection. US FDA-approved manufacturer's package insert. Available from: [accessed on October 12 2012]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021344s007s012lbl.pdf.
15. Freedman O., et al. Predicting benefit from fulvestrant in pretreated metastatic breast cancer patients. Breast Cancer Res Treat 2009, 118(2):377-383.
16. Robertson J.F., et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009, 27(27):4530-4535.
17. http://www.clinicaltrials.gov/ct2/show/NCT01602380.
18. Shemilt I, Mugford M, Byford S, et al. Analysing and presenting results. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org.
19. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7(3):177-188.
20. Sweeting M.J., Sutton A.J., Lambert P.C. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med 2004, 23(9):1351-1375.
21. Higgins JPT, Deeks JJ, Altman DG. Metaanalysis of rare events. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions (version 5.1.0). The Cochrane Collaboration; 2011. http://www.cochrane-handbook.org.
22. Deeks J.J. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001, 323(7305):157-162.
23. Robertson JFR, Lindemann JPO, Llombart-Cussac A, et al. A comparison of fulvestrant 500mg with anastrozole as first-line treatment for advanced breast cancer: follow-up analysis from the 'FIRST' study. San Antonio Breast Cancer Symposium, San Antonio (TX), December 8-12; 2010 (abstr. S1-3).
24. Yoneya T., et al. Thiochroman derivative CH4986399, a new nonsteroidal estrogen receptor down-regulator, is effective in breast cancer models. Anticancer Res 2010, 30(3):873-878.
25. Fan M., et al. Characterization of molecular and structural determinants of selective estrogen receptor downregulators. Breast Cancer Res Treat 2007, 103(1):37-44.
26. Hershman D.L., et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8769 early-stage breast cancer patients. J Clin Oncol 2010, 28(27):4120-4128.
27. Amir E., et al. Defining ovarian failure in amenorrheic young breast cancer patients. Breast 2010, 19(6):545-548.
28. Amir E., et al. Amenorrhoea, menopause, and endocrine therapy for breast cancer. BMJ 2009, 3(339).
29. European Medicines Agency. Faslodex: summary of product characteristics. Available from: [accessed October 20 2012]. http://www.emea.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000540/WC500021174.pdf.
30. [last accessed on October 29 2012]. http://clinicaltrials.gov/show/NCT00075764.